BUPIVACAINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Bupivacaine Hydrochloride patents expire, and when can generic versions of Bupivacaine Hydrochloride launch?
Bupivacaine Hydrochloride is a drug marketed by Civica, Eugia Pharma, Hikma Pharms, Hospira, Kindos, Somerset, Steriscience, B Braun Medical Inc, Baxter Hlthcare Corp, Huons, and Intl Medicated. and is included in thirty-three NDAs.
The generic ingredient in BUPIVACAINE HYDROCHLORIDE is bupivacaine hydrochloride; epinephrine bitartrate. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride; epinephrine bitartrate profile page.
Summary for BUPIVACAINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 33 |
Finished Product Suppliers / Packagers: | 17 |
Raw Ingredient (Bulk) Api Vendors: | 119 |
Clinical Trials: | 1,623 |
Patent Applications: | 753 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BUPIVACAINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for BUPIVACAINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University Hospital "Sestre Milosrdnice" | N/A |
National Trauma Center | N/A |
Johnny K. Lee | Phase 4 |
Pharmacology for BUPIVACAINE HYDROCHLORIDE
Drug Class | Amide Local Anesthetic |
Physiological Effect | Local Anesthesia |